Redasemtide + Placebo
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Ischemic Stroke
Conditions
Acute Ischemic Stroke
Trial Timeline
Jul 14, 2023 → Mar 31, 2026
NCT ID
NCT05953480About Redasemtide + Placebo
Redasemtide + Placebo is a phase 2 stage product being developed by Shionogi for Acute Ischemic Stroke. The current trial status is active. This product is registered under clinical trial identifier NCT05953480. Target conditions include Acute Ischemic Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischemic Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05953480 | Phase 2 | Active |
Competing Products
20 competing products in Acute Ischemic Stroke